IGC Pharma, Inc. NYSE American: IGC (@IGCIR) header
IGC Pharma, Inc. NYSE American: IGC (@IGCIR) profile picture

NYSE American: IGC | Advancing Alzheimer's research through therapeutic innovation and AI

Maryland, US.
Joined October 2013
Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)Photo by IGC Pharma, Inc. NYSE American: IGC (@IGCIR)
CALMA enrolled people with agitation in Alzheimer’s dementia at sites across the U.S. and Canada. Participants receive investigational IGC-AD1 or placebo for six weeks. $IGC igcpharma.com/igc-ad1-phase-…
1
102
Agitation in Alzheimer’s can look like restlessness, yelling or pushing back against help with everyday tasks. It’s one of the hardest parts of the disease for families to manage. $IGC
1
3
119
Thank you to the investigators and site teams running CALMA, our Phase 2 trial of investigational IGC-AD1, across the U.S. and Canada. $IGC
1
1
2
164
Evelyn Gutiérrez, our Associate Director of Research and Clinical Trials, on what drives her work in Alzheimer’s research. $IGC
1
90
November is National Alzheimer’s Disease Awareness Month and National Family Caregivers Month. Some of the hardest moments in Alzheimer’s come from symptoms beyond memory loss, like agitation. Agitation is the focus of CALMA, our Phase 2 trial of investigational IGC-AD1. $IGC igcpharma.com/igc-ad1-phase-…
2
121
Two ways we’re applying AI to Alzheimer’s: • MINT-AD, our patent-pending platform for Alzheimer’s risk insights, moving toward real-world use through PRISM • aha™, which harmonizes research data from different studies igcpharma.com
2
129
In a double-blind trial, neither participants nor their doctors know who is receiving the investigational drug and who is receiving placebo. It keeps expectations from shaping the results, which is why it’s the standard design for testing a new treatment.
1
4
358
Clinical agitation in Alzheimer’s isn’t a bad mood. It’s a symptom of the disease, and one of the hardest for families to manage. What it is, in 90 seconds: #AlzheimersResearch
1
167
Combining Alzheimer’s data from different studies takes researchers hours of manual work. aha™, our AI tool, cut one representative workflow from 28 hours to 2.5, with a person reviewing the results. It will be deployed on the Alzheimer’s Disease Data Initiative’s (@AlzData) research platform.
1
1
175
Behavioral and psychological symptoms add another layer of complexity to Alzheimer's disease. Their variability is one reason researchers continue to study how they develop and change over time. #AlzheimersResearch
2
2
201
PRISM is the latest step in IGC Pharma's Alzheimer's AI strategy Designed to bring the patent-pending MINT-AD platform closer to real-world healthcare applications, PRISM is intended to move AI-generated Alzheimer's risk insights into action Read more: igcpharma.com/igc-pharma-unv… #AlzheimersResearch
4
2
251
Most people associate Alzheimer's disease with memory loss But researchers believe biological changes associated with Alzheimer's may begin 10–20 years before symptoms become noticeable  Alzheimer's Association (2026) #AlzheimersResearch ↓
1
2
2
277
Studying Alzheimer's before symptoms appear helps researchers investigate the disease at its earliest stages, before significant damage has occurred This may help improve how clinical studies are designed and how potential therapies are evaluated National Institute on Aging (2025)
1
26
Understanding what happens before symptoms appear is one of the keys to advancing Alzheimer's research #Neuroscience #BrainHealth
24